NOTE: As provided in LFC policy, this report is
intended only for use by the standing finance committees of the
legislature. The Legislative Finance Committee does not assume
responsibility for the accuracy of the information in this report when used for
other purposes.
The most recent FIR
version (in HTML & Adobe PDF formats) is available on the Legislative
Website. The Adobe PDF version includes
all attachments, whereas the HTML version does not. Previously issued FIRs and attachments may be
obtained from the LFC in
|
SPONSOR: |
Hurt |
DATE TYPED: |
|
HB |
|
||
|
SHORT TITLE: |
Prescription Drug Copayments |
SB |
647 |
||||
|
|
ANALYST: |
|
|||||
APPROPRIATION
|
Appropriation
Contained |
Estimated
Additional Impact |
Recurring or
Non-Rec |
Fund Affected |
||
|
FY03 |
FY04 |
FY03 |
FY04 |
|
|
|
|
|
|
See Narrative |
|
|
Responses
Received From
Health
Policy Commission (HPC)
Board
of Pharmacy (BP)
SUMMARY
Synopsis
of Bill
Senate Bill 647 enacts
a new section of the New Mexico Drug, Device and Cosmetic Act requiring
copayments for prescription drugs that are advertised directly to
consumers. These new copayments are in
addition to insurance copays, and will go to the drugs’ manufacturer. The copayment
will be 20% of the cost of the prescription drug.
SB 647 requires drug
manufacturers to provide pharmacies on a monthly basis a list of prescription
drugs advertised for which the advertising co-payment applies.
Significant
Issues
SB 647 appears to be an attempt to curtail the
advertising of drugs by forcing the consumer to pay out of his own pocket for
these products.
FISCAL IMPLICATIONS
It is not clear how the provisions of SB 647
will be enforced, but when this is clarified there will be some fiscal impact
to the enforcing agency.
POSSIBLE QUESTIONS
Does SB 647 apply to medicaid and
medicare recipients?